All Drugs Can Be Considered Medicines.

All Drugs Can Be Considered Medicines: Unpacking a Provocative Statement

The assertion that “all drugs can be considered medicines” immediately challenges a fundamental distinction most of us internalize from childhood. We are taught to categorize substances into clear boxes: the “good” medicines in the pharmacy, prescribed to heal, and the “bad” drugs on the street, used to escape or harm. This binary thinking is reinforced by law, media, and public health campaigns. Yet, upon closer inspection, this boundary is far more permeable and historically contingent than we often acknowledge. At its core, the statement forces us to separate the chemical entity from its context of use, its social perception, and its legal status. Scientifically, a drug is simply a substance that, when absorbed into the body, alters its function—typically by affecting the central nervous system. A medicine is a drug used with the intent to prevent, diagnose, treat, or cure disease or to promote well-being. The critical, often contentious, question is: who defines “disease” and “well-being,” and under what circumstances does a drug’s effect transition from “medical” to “recreational” or “abuse”?

Defining the Terms: Drug vs. Medicine

To dissect this idea, we must first establish precise definitions. The term drug is a broad, neutral pharmacological category. It originates from the Dutch droog (dry), referring to dried medicinal plants, but now encompasses any chemical substance that has a physiological effect when ingested or otherwise introduced into the body. This includes caffeine in your morning coffee, nicotine in a cigarette, ethanol in wine, and the molecules in a chemotherapy infusion. By this definition, all medicines are drugs, but the reverse is not inherently true.

A medicine (or medication) is a subset of drugs. It is a drug employed for a therapeutic purpose within a framework of medical practice. This implies several key components: a diagnosed condition (e.g., hypertension, infection, pain), a prescribed or recommended dosage and regimen, an expectation of benefit outweighing risk, and typically, regulation and oversight by health authorities like the FDA or EMA. The transformation from “drug” to “medicine” is not an intrinsic property of the molecule itself but is conferred by its application within a healing paradigm. Aspirin (acetylsalicylic acid) is a drug. When taken to reduce a fever or prevent a heart attack under a doctor’s guidance, it becomes a medicine. The same molecule, if taken in excess to induce a dangerous, non-therapeutic state, is an overdose of a drug with harmful consequences.

The Central Role of Context, Dose, and Intent

The maxim “the dose makes the poison,” attributed to Paracelsus, is the cornerstone of toxicology and perfectly illustrates this point. Context is everything. Consider opium. The dried latex from the poppy Papaver somniferum contains alkaloids like morphine. For millennia, it was used as a powerful painkiller and sedative in various traditional medicines. Isolated and purified, morphine became a cornerstone of modern surgical anesthesia and palliative care—a quintessential medicine. The same molecule, when illicitly processed into heroin and injected to achieve euphoria outside a medical framework, is classified as an illegal drug with a high potential for addiction and devastation. The chemical structure is identical; the societal and medical context is what differs.

Similarly, cannabis (marijuana) contains cannabinoids like THC and CBD. For most of the 20th century in many countries, any use was deemed illicit “drug use.” Today, a growing body of evidence supports the use of specific cannabinoids for treating chronic pain, chemotherapy-induced nausea, and certain epilepsy syndromes. In jurisdictions where it is legal for these purposes, it is dispensed as a medicine by licensed practitioners. Yet, its recreational use for relaxation or altered states remains, in those same jurisdictions, a separate legal and social category. The plant material is the same; the intended use and regulatory pathway define its classification.

Even everyday substances blur these lines. Caffeine is a psychoactive drug. Consumed in coffee or tea for alertness and pleasure, it is a widely accepted, unregulated dietary component. However, in pill form, it can be used medically to treat apnea of prematurity in newborns or as a diagnostic agent. Alcohol (ethanol) is a central nervous system depressant drug. Its use in tinctures (like tincture of benzoin) is medicinal. Its social consumption as a beverage is culturally normalized, though its health impacts are complex and dose-dependent. The line between “social use” and “problem use” is itself a spectrum defined by patterns, consequences, and medical judgment.

The Social and Legal Construction of “Medicine”

If the scientific definition is fluid, the legal and social definitions are even more so. The status of a substance as a “medicine” is largely a social and legal construct that reflects cultural values, political power, economic interests, and historical moment.

The regulatory process is the primary gatekeeper. A drug becomes a “medicine” when

…granted marketing authorization after demonstrating, to the satisfaction of a regulatory authority such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or comparable national bodies, that the substance is safe, effective, and manufactured to consistent quality standards for a specified therapeutic indication. This process typically involves pre‑clinical studies, phased clinical trials (Phase I–III), and, for many products, post‑marketing surveillance (Phase IV) to monitor rare or long‑term adverse effects. Only when the accumulated evidence meets the statutory threshold of “substantial evidence of effectiveness” and a favorable risk‑benefit balance does the agency issue a license that permits the product to be labeled, advertised, and dispensed as a medicine.

Beyond the technical criteria, the decision to approve a substance is intertwined with broader societal judgments. Political lobbying, public health emergencies, and advocacy movements can accelerate or impede review timelines—as seen with the rapid Emergency Use Authorizations for COVID‑19 vaccines and the decades‑long rescheduling debates surrounding psychedelics. Economic considerations also play a role: patent protections, market exclusivity periods, and reimbursement policies influence whether a sponsor invests in the costly clinical development required for medicinal status. Consequently, a compound may possess demonstrable pharmacological activity yet remain outside the medicinal sphere because its developers lack the resources or incentive to navigate the regulatory pathway, or because policymakers deem its therapeutic niche insufficient to justify formal approval.

The social construction of “medicine” is further evident in the phenomenon of off‑label use. Physicians may prescribe an approved drug for indications not captured in its label when clinical experience or emerging data suggest benefit. While such practice is legally permissible in many jurisdictions, it highlights the gap between regulatory boundaries and real‑world therapeutic flexibility. Conversely, substances that are widely used recreationally may acquire medicinal legitimacy through patient‑driven demand, prompting re‑evaluation of their scheduling status—illustrated by the shifting classifications of cannabidiol‑rich cannabis extracts and certain psychedelic compounds in recent years.

Ultimately, the label “medicine” is not an immutable property of a molecule but a dynamic designation that emerges at the intersection of scientific evidence, regulatory gatekeeping, cultural attitudes, and economic forces. Recognizing this fluidity encourages a more nuanced approach to drug policy: one that evaluates substances on the basis of their actual use, risks, and benefits rather than relying solely on historical categorizations or moral panics. By aligning legal frameworks with evolving clinical insights and public health priorities, societies can better harness therapeutic potential while minimizing harm, ensuring that the distinction between drug and medicine serves patients and communities rather than arbitrary precedent.